EUVIMEDEUVIMED entdecken
Crossref

Does Maintenance Therapy Improve Survival of Patients With Intermediate-Risk Rhabdomyosarcoma Treated With VAC/VI Regimen? A Report From the Children's Oncology Group

Sapna Oberoi, Wei Xue, Amria Qumseya, Christine M. Heske, Douglas J. Harrison, Douglas S. Hawkins, Erin R. Rudzinski, Suzanne L. Wolden, Roshni Dasgupta, Abha A. Gupta, Rajkumar Venkatramani

JCO Oncology Advances · 2026-10 · 3 (4)

DOI: 10.1200/oa-26-00088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-10. Verfasst von Sapna Oberoi und 10 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The primary objective of this analysis was to compare survival outcomes of patients with intermediate-risk rhabdomyosarcoma (IR-RMS) treated with vincristine, actinomycin-D, and cyclophosphamide alternating with vincristine and irinotecan (VAC/VI) + vinorelbine and cyclophosphamide (VinoC) maintenance on ARST1431 versus VAC/VI on ARST0531 to evaluate whether VinoC maintenance improves survival when added to the VAC/VI regimen. Secondary objectives included survival comparisons of patients with IR-RMS treated with VAC/VI + VinoC, VAC 1200 in ARST0531, and VAC 2200 in D9803 trials.

Methods

Event-free survival (EFS) and overall survival (OS) of patients with stage II/III, group 3 embryonal RMS and nonmetastatic alveolar RMS treated with VAC/VI on ARST0531 trial were compared with those treated with VAC/VI + VinoC maintenance on the ARST1431 trial using an inverse probability of treatment weighting (IPTW) adjusted Cox proportional hazards regression model. Survival comparisons of patients with IR-RMS treated with VAC/VI + VinoC, VAC 1200 , and VAC 2200 were performed using the log-rank test.

Results

The 4-year EFS and OS of patients treated with VAC/VI + VinoC versus VAC/VI were 60.9% (95% CI, 49.9 to 71.9) versus 58.7% (95% CI, 52 to 65.4; log-rank P = .68) and 78.0% (95% CI, 68.7 to 87.2) versus 72.3% (95% CI, 66.1 to 78.4; log-rank P = .29), respectively. After IPTW adjustment, no significant difference was observed between EFS of patients with IR-RMS treated with VAC/VI + VinoC versus those treated with VAC/VI (hazard ratio [HR], 0.88 [95% CI, 0.69 to 1.12]; P = .28). Similarly, OS did not differ significantly between the two groups (HR, 0.80 [95% CI, 0.59 to 1.08]; P = .15). There were no statistically significant differences in 4-year EFS or OS between patients treated with VAC/VI + VinoC on ARST1431 and those treated with either VAC 1200 on ARST0531 or VAC 2200 on D9803 trials.

Conclusion

Nonrandomized comparative analysis demonstrated that incorporating VinoC maintenance after VAC/VI treatment did not improve survival of patients with IR-RMS compared with VAC/VI.

Zitieren

APA

Oberoi, S., Xue, W., Qumseya, A., Heske, C. M., Harrison, D. J., Hawkins, D. S., Rudzinski, E. R., Wolden, S. L., Dasgupta, R., Gupta, A. A., & Venkatramani, R. (2026). Does Maintenance Therapy Improve Survival of Patients With Intermediate-Risk Rhabdomyosarcoma Treated With VAC/VI Regimen? A Report From the Children's Oncology Group. JCO Oncology Advances, 3(4). https://doi.org/10.1200/oa-26-00088

Vancouver

Oberoi S, Xue W, Qumseya A, Heske CM, Harrison DJ, Hawkins DS, et al. Does Maintenance Therapy Improve Survival of Patients With Intermediate-Risk Rhabdomyosarcoma Treated With VAC/VI Regimen? A Report From the Children's Oncology Group. JCO Oncology Advances. 2026;3(4). doi:10.1200/oa-26-00088

BibTeX
@article{Oberoi2026,
  author = {Oberoi, Sapna and Xue, Wei and Qumseya, Amria and Heske, Christine M. and Harrison, Douglas J. and Hawkins, Douglas S. and Rudzinski, Erin R. and Wolden, Suzanne L. and Dasgupta, Roshni and Gupta, Abha A. and Venkatramani, Rajkumar},
  title = {Does Maintenance Therapy Improve Survival of Patients With Intermediate-Risk Rhabdomyosarcoma Treated With VAC/VI Regimen? A Report From the Children's Oncology Group},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {4},
  doi = {10.1200/oa-26-00088}
}
Kostenlos starten →